Christopher Haas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher Haas has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Itzhak Fischer
Department of Neurobiology and Anatomy, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, USA
1 shared publication Jody Borgman
Department of Internal Medicine/Infectious Disease, Einstein Medical Center, Philadelphia, Pennsylvania, USA
1 shared publication- Julien Bouyer
Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA 19129, USA
1 shared publication - Kazuo Hayakawa
Department of Orthopaedic Surgery, Garduate School of Medical Sciences, Nagoya City University, Nagoya, Japan †Drexel University College of Medicine, Philadelphia, PA ‡Department of Rehabilitation Medicine, Garduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
1 shared publication Mary Rodriguez Ziccardi
Department of Internal Medicine, Einstein Medical Center, Philadelphia, Pennsylvania, USA
1 shared publication- Takanobu Otsuka
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan
1 shared publication
Latest Publications
- 15 December 2015
- Published by BMJ in BMJ Case Reports
- Vol. 2015
Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient
Abacavir hypersensitivity is a rare, yet significant adverse reaction that results in a spectrum of physical and laboratory abnormalities, and has been postulated to stem from a variety of aetiological factors. The major histocompatibility complex haplotype human leucocyte antigen (HLA)-B5701 is a significant risk factor in development of hypersensitivity reactions, yet only 55% of HLA-B5701+ individuals develop such reactions, suggesting a multifactorial aetiology. Nevertheless, prospective screening and avoidance of abacavir in these patients has limited adverse events. Within this spectrum of adverse events, abacavir-induced liver toxicity is exceedingly rare and reported events have ranged from mild elevations of aminotransferases to fulminant hepatic failure. We report the case of a 50-year-old Caucasian woman with a history significant for HIV, hepatitis C virus and a HLA-B5701+ status, transferred to our emergency department in a hypotensive state and found to have acute liver failure, acute renal failure and significant rhabdomyolysis following a change of highly active antiretroviral therapy regimen.
- 15 December 2015
- Published by BMJ in BMJ Case Reports
- Vol. 2015
Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient
Abacavir hypersensitivity is a rare, yet significant adverse reaction that results in a spectrum of physical and laboratory abnormalities, and has been postulated to stem from a variety of aetiological factors. The major histocompatibility complex haplotype human leucocyte antigen (HLA)-B5701 is a significant risk factor in development of hypersensitivity reactions, yet only 55% of HLA-B5701+ individuals develop such reactions, suggesting a multifactorial aetiology. Nevertheless, prospective screening and avoidance of abacavir in these patients has limited adverse events. Within this spectrum of adverse events, abacavir-induced liver toxicity is exceedingly rare and reported events have ranged from mild elevations of aminotransferases to fulminant hepatic failure. We report the case of a 50-year-old Caucasian woman with a history significant for HIV, hepatitis C virus and a HLA-B5701+ status, transferred to our emergency department in a hypotensive state and found to have acute liver failure, acute renal failure and significant rhabdomyolysis following a change of highly active antiretroviral therapy regimen.
- 1 December 2015
- Published by Elsevier in Brain Research
- Vol. 1629, 113-125
Glial restricted precursors maintain their permissive properties after long-term expansion but not following exposure to pro-inflammatory factors
- 1 December 2015
- Published by Elsevier in Brain Research
- Vol. 1629, 113-125
Glial restricted precursors maintain their permissive properties after long-term expansion but not following exposure to pro-inflammatory factors
- 25 January 2012
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 28 (2) , 241-281
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Therapeutic options for Alzheimer's disease are currently limited to symptomatic treatment that only provides modest and temporary maintenance of cognitive and memory functions, without altering disease progression. Although a variety of therapeutics targeting amyloid production or plaque degradation as well as tau hyperphosphorylation and aggregation have been proposed, examined in pre-clinical models and introduced into clinical trials, many have failed to provide significant therapeutic benefit. Concerns over the adequacy of currently used pre-clinical models, in addition to questions pertaining to the timing of therapeutic administration, vis-à-vis synaptic and neuronal loss have been raised, and are further complicated by the genetic diversity of individual patients. This review will provide a brief overview of Alzheimer's disease pathophysiology and the currently approved therapeutics, while the main section will focus on therapeutics currently evaluated in pre-clinical models and clinical trials.
- 25 January 2012
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 28 (2) , 241-281
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Therapeutic options for Alzheimer's disease are currently limited to symptomatic treatment that only provides modest and temporary maintenance of cognitive and memory functions, without altering disease progression. Although a variety of therapeutics targeting amyloid production or plaque degradation as well as tau hyperphosphorylation and aggregation have been proposed, examined in pre-clinical models and introduced into clinical trials, many have failed to provide significant therapeutic benefit. Concerns over the adequacy of currently used pre-clinical models, in addition to questions pertaining to the timing of therapeutic administration, vis-à-vis synaptic and neuronal loss have been raised, and are further complicated by the genetic diversity of individual patients. This review will provide a brief overview of Alzheimer's disease pathophysiology and the currently approved therapeutics, while the main section will focus on therapeutics currently evaluated in pre-clinical models and clinical trials.